Shanghai Hengrui Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2001-12-04

Employees: -

Market Cap: -

Website: http://www.shhrp.com

Clinical Trials

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: SHR-9839

First Posted Date: 2023-05-01

Last Posted Date: 2023-05-09

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 174

Registration Number: NCT05836948

Locations: 🇨🇳
Zhejiang Tumor Hospital, Hangzhou, Zhejiang, China

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Biological: Adebrelimab
Biological: SHR-1802
Drug: Carboplatin/Cisplatin
Drug: Paclitaxel/Nab-Paclitaxel/Pemetrexed

First Posted Date: 2023-04-03

Last Posted Date: 2023-06-02

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 132

Registration Number: NCT05794477

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

Phase 3

Completed

Conditions: Postsurgical Pain Management

Interventions: Drug: HR18034
Drug: Sodium Chloride Physiological Solution
Drug: ropivacaine HCl

First Posted Date: 2023-03-15

Last Posted Date: 2024-03-07

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 294

Registration Number: NCT05769855

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management

Phase 2

Recruiting

Conditions: Thoracoscopic Lobectomy

Interventions: Drug: HR18034
Drug: Ropivacaine Hydrochloride Injection

First Posted Date: 2023-02-27

Last Posted Date: 2023-03-15

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT05744674

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-7367

First Posted Date: 2023-02-22

Last Posted Date: 2023-05-12

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 182

Registration Number: NCT05740202

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Phase 1

Recruiting

Conditions: Advanced Or Metastatic Solid Tumor Malignancies

Interventions: Drug: SHR-A2102

First Posted Date: 2023-02-21

Last Posted Date: 2023-03-28

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 252

Registration Number: NCT05735275

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-A2102

First Posted Date: 2023-01-27

Last Posted Date: 2023-05-31

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT05701709

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Phase 1

Recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: SHR-1707
Drug: SHR-1707 placebo

First Posted Date: 2023-01-12

Last Posted Date: 2023-05-09

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 41

Registration Number: NCT05681819

Locations: 🇨🇳
The First Affiliated Hospital Of USTC, Hefei, Anhui, China

A Study of SHR6508 in Secondary Hyperparathyroidism

Phase 2

Active, not recruiting

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: SHR6508
Drug: Cinacalcet

First Posted Date: 2022-12-23

Last Posted Date: 2023-06-18

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 75

Registration Number: NCT05663411

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: SHR-1905
Drug: placebo

First Posted Date: 2022-10-25

Last Posted Date: 2024-06-24

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 248

Registration Number: NCT05593250

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy